$EVMN

Drew Janice Suzann sold $453K of EVMN

Drew Janice Suzann (Chief of Dev. Operations) sold 20,000 shares of Evommune, Inc. (EVMN) at $22.63 ($0.45M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Drew Janice Suzann
Published Jun 25, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 25, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EVMN
Neutral
high confidence
Mentioned
$EVMN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVMNNeutralLow
01

Why it matters

A pre-arranged 10b5-1 open-market sale by an officer is typically treated as lower-signal than discretionary selling, and the filing contains no new company-specific catalyst.

02

Market read

Traders may log the sale for positioning/flow monitoring, but it is unlikely to drive a fresh fundamental repricing by itself.

03

What to watch

The article provides only one sale; without context on prior insider activity, total insider net selling, or any concurrent corporate events, signal strength is limited.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-24 for a 2026-06-22 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Evommune, Inc. (EVMN).

Company-level read

Ticker impact

$EVMNNeutralHigh confidence
Context

Evommune insider Drew Janice Suzann sold 20,000 shares in an open-market transaction at $22.63 on 2026-06-22.

Expected impact

Low likelihood of a sustained price move solely from this disclosure.

Evidence & confidence

The filing is a disclosed insider sale with a pre-arranged 10b5-1 plan; no new company fundamentals, guidance, or enforcement action are mentioned.

Market effects

No sector read-through; this is a single insider transaction with no operational or regulatory linkage.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution; traders may watch for follow-on sales.

Key entities

  • Evommune, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Drew Janice Suzann

    Chief of Dev. Operations who sold shares under a 10b5-1 plan.

Related articles

$EVMNMed

Evommune, Inc. (EVMN): Results of Operations and Financial Condition

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial